An Open-label, Multicenter, Dose Escalation, First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered RO7507062 in Participants With Systemic Lupus Erythematosus
Latest Information Update: 18 Jun 2025
At a glance
- Drugs RO-7507062 (Primary) ; Tocilizumab (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions; First in man
- Sponsors Roche
Most Recent Events
- 15 Jun 2024 Trial design, presented at the 25th Annual Congress of the European League Against Rheumatism
- 02 Nov 2023 Planned initiation date (estimated date of first participant enrollment) changed from 31 Oct 2023 to 30 Nov 2023.
- 02 Nov 2023 Status changed from not yet recruiting to recruiting.